New eczema cream shows promise for kids in early safety trial

NCT ID NCT05186805

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times

Summary

This study looked at how safe a new cream called tapinarof is for children aged 2 to 17 with moderate to severe eczema covering large areas of their body. Researchers checked for side effects and measured how much of the drug got into the bloodstream. The goal was to see if the cream could be used safely in young patients with extensive eczema.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dermavant Investigative Site

    Thousand Oaks, California, 91320, United States

  • Dermavant Investigative Site

    Centennial, Colorado, 80112, United States

  • Dermavant Investigative Site

    Coral Gables, Florida, 33146, United States

  • Dermavant Investigative Site

    Hialeah, Florida, 33016, United States

  • Dermavant Investigative Site

    Miami Lakes, Florida, 33014, United States

  • Dermavant Investigative Site

    Chicago, Illinois, 60611, United States

  • Dermavant Investigative Site

    Summerville, South Carolina, 29445, United States

  • Dermavant Investigative Site

    Houston, Texas, 77030, United States

  • Dermavant Investigative Site

    San Antonio, Texas, 78213, United States

  • Dermavant Investigative Site

    Calgary, Alberta, T3A 2N1, Canada

Conditions

Explore the condition pages connected to this study.